• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22472 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Precice® motorized intramedullary nail system for limb-length discrepancy]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Precice® intramedullary nail system, with external remote controller, for limb length discrepancy]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Pre-hospital ECMO for refractory cardiac arrest]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Prasugrel in the treatment of acute coronary syndrome]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pralsetinib (RET fusion-positive NSCLC) - Benefit assessment according to §35a Social Code Book V]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Power Doppler for inflammatory arthropathies]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Powder bed fusion manufacturing of titanium for customized bone replacements in craneomaxillofacial reconstruction]
1999     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Postoperative use of antiembolism stockings: patient's use, practice and information]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Postoperative pain treatment at home with an elastomeric pump - a health technology assessment]
2023     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Postoperative antimicrobial prophylaxis for thoracic surgery]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Posterior tibial nerve stimulation in overactive bladder]
2015     The Swedish Council on Health Technology Assessment (SBU) [Post-mortem imaging]
2019     Andalusian Health Technology Assessment Area (AETSA) [Post-introduction observational study of predictive/prognostic tests in breast cancer of the Andalusian Public Health System (SSPA)]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post COVID-19 – effective treatment and rehabilitation]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Positron-emission tomography for breast cancer]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Positron emissions tomography (PET) with 18-F-fluorodeoxyglucose (FDG)]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Positron emission tomography: proposal for prioritization of indications]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Positron emission tomography in combination with computed tomography (PET/CT) in minimal cognitive impairment and dementias]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Positron emission tomography (PET)]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Positron emission tomography (PET): diagnostic usefulness and indications]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in recurrent colorectal cancer]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in ovarian cancer]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in oesophagus cancer]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in malignant melanoma]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in malignant lymphoma]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in high-grade malignant glioma (grades III and IV)]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in head and neck tumours]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in bone and soft tissue tumors]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Positron emission tomography (pet) for routine follow-up of selected neoplasms]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Posaconazole for invasive fungal infection treatment and prevention in neutropenic patients]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Portraits describing pharmacological and non-pharmacological interventions for attention deficit hyperactivity disorder (ADHD) in Quebecers 25 years of age and under]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Portrait of coronary revascularization by percutaneous coronary intervention and coronary bypass grafting in Quebec, 2015-2018]
2022     Canary Health Service [Portable neuromodulation stimulation device to improve gait in multiple sclerosis]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Portable home hemodialysis systems]
2023     Norwegian Institute of Public Health (NIPH) [Portable ECG equipment for the diagnosis of atrial fibrillation in the specialist health care: rapid HTA - scoping review]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Portable automated sputum suction]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Porcine biological prosthesis for the management of anal fistula]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Population ultrasound screening for abdominal aortic aneurysms]
2011     Health Council of the Netherlands Gezondheidsraad (GR) [Population screening for cervical cancer]
2015     Health Council of the Netherlands Gezondheidsraad (GR) [Population Screening Act: prevalence of gastrointestinal tract disorders studied with a video capsule]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponatinib (Philadelphia chromosome positive acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponatinib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponatinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide: benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide for relapsed and refractory myeloma]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide combined with dexamethasone in multiple myeloma]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide (multiple myeloma) - Addendum to Commission A19-50]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment))]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide - Addendum to Commission A15-42]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Polysomnography in the diagnosis of sleep-related breathing disorders]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone for DLBCL – Benefit assessment according to § 35a Social Code Book V]
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Point-of-care testing in the private sector]
2018     Andalusian Health Technology Assessment Area (AETSA) [Point of care test for differential diagnosis of virus versus bacteria in acute respiratory tract infection]
2009     Committee for New Health Technology Assessment (CNHTA) [POCT(point of care test) prothrombin time]
2009     Committee for New Health Technology Assessment (CNHTA) [PMS2 gene mutation analysis(sequencing)]
2009     Committee for New Health Technology Assessment (CNHTA) [PMP22 exon deletion/duplication test [MLPA]]
2010     Committee for New Health Technology Assessment (CNHTA) [PLP1 gene deletion/duplication test[MLPA]]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Plerixafor (Mozobil) in patients with lymphoma and multiple myeloma]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Platform to analyse RNA, DNA or proteins as biomarkers in the diagnosis, prognosis and assessment of treatments]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in orthopedic diseases]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in maxillofacial surgery]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in fractures and bone pseudoarthrosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in diabetic foot ulcers]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in certain orthopedic conditions]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Platelet transfusion in cerebral haemorrhage (PATCH)]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet rich plasma in musculoskeletal conditions]
2007     Andalusian Health Technology Assessment Area (AETSA) [Planned home birth. Current situation in developed countries]
2007     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Place of hyperbaric oxygen therapy in the management of cerebral palsy]
2010     Haute Autorite de sante (HAS) [Place of Breast MRI in the pre-treatment locoregional spread assessment of breast cancer]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pixantrone - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (sleep apnoea) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (narcolepsy) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (narcolepsy, with or without cataplexy, children and adolescents, 6-17 years) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Pirfenidone in pulmonary fibrosis]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pirfenidone - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Pipeline embolization device]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pilot study: conjoint analysis in the indication "hepatitis C"]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pilot study: analytic hierarchy process in the indication "major depression"]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Pilot study to identify and assess obsolete health technologies from emerging technologies identification databases]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [Pilot study for understanding the present situation of decorative tattoos]
2009     Committee for New Health Technology Assessment (CNHTA) [PIGA (Phosphatidyl inositol glycan-Class A) mutation analysis]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [PICC line insertion by navigation system and confirmation of the catheter tip by intracavitary electrocardiogram]
2012     Haute Autorite de sante (HAS) [Physiotherapeutic treatment of lymphoedema and shoulder stiffness after breast cancer treatment]
2020     Canary Health Service [Physical exercise intervention in older hospitalized patients for the prevention of functional and cognitive deterioration during hospital admission]
2009     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Physical disease in schizophrenia: systematic review and analysis of hospital records]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Phototherapy and systemic treatment for moderate to severe psoriasis]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Photoselective vaporization for benign prostatic hyperplasia with KTP (potassium-titanyl-phosphate) laser or GreenLight]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Photopheresis in treatment of steroid-refractory acute graft-versus-host disease]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Photodynamic treatment of subretinal new vessels of choroidal origin in age-related macular degeneration - an HTA]
2020     National Committee for Technology Incorporation (CONITEC) [Photodynamic therapy for non-melanoma skin cancer]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for non-melanocytic skin cancer treatment]